UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 19, 2011

Tibet Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

British Virgin Islands	001-35038	Not Applicable
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

Room 1701, 17/F

90 Jaffe Rd.

Wanchai, Hong Kong

(Address of Principal Executive Office) (Zip Code)

(852) 9798 5569

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01 OTHER EVENTS

On April 19, 2011, the Registrant issued a press release announcing the issuance of an in-depth initiation report by Patrick Murphy, CFA, principal of the fee-based, third-party research firm Murphy Analytics, which report discusses the Registrant, its current portfolio of five traditional Tibetan medicine, and initiating coverage with a 12-month price target of $11.00 per share.

On April 21, 2011, the Registrant issued a press release announcing the release of an online corporate overview video that provides a concise overview of the Registrant’s specialty medicines and growth opportunities in China’s expanding healthcare industry.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(a) Financial statements of businesses acquired.

Not Applicable.

(b) Pro forma financial information.

Not Applicable.

(c) Shell company transactions.

Not Applicable.

(d) Exhibits.

99.01	Press Release of April 19, 2011: “Detailed Report Targets 12-Month Price of $11.00”
99.02	Murphy Analytics Report: “Initiating Coverage: Tibet Pharmaceuticals, Inc.”
99.03	Press Release of April 21, 2011: “Video Speaks to Tibet Pharmaceuticals’ Specialty Medicines and Growth Opportunity in China’s Expanding Healthcare Industry”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	Tibet Pharmaceuticals, Inc.
Date: April 22, 2011	By:	/s/ Taylor Z. Guo
		Taylor Z. Guo
		Chief Executive Officer

EXHIBIT INDEX

Number	Description of Exhibit
99.01	Press Release of April 19, 2011: “Detailed Report Targets 12-Month Price of $11.00”
99.02	Murphy Analytics Report: “Initiating Coverage: Tibet Pharmaceuticals, Inc.”
99.03	Press Release of April 21, 2011: “Video Speaks to Tibet Pharmaceuticals’ Specialty Medicines and Growth Opportunity in China’s Expanding Healthcare Industry”